Navigation Links
Old is gold– proved yet another tim

Chloroquine, an antimalarial drug was highly successful in combating the disease when launched in the 1950s.// It soon became useless because of resistance being developed by the malarial parasite.

Scientists have found a way to breathe new life into the drug. It has been found that combining the drug with another preparation, Primaquine, would restore the effect of the original drug.

Malaria is caused by the parasite Plasmodium falciparum and is associated with a significant mortality all over the world, especially in the developing countries.

Chloroquine - which is far cheaper than more modern malaria drugs - works by blocking the way the parasite breaks down human hemoglobin contained in red blood cells. If the haem molecules remain in an uncrystallised form, they are toxic to the parasite, thereby killing it.

On its own, primaquine has no effect on P. falciparum, but it is structurally similar to chloroquine. The right concentration and combination of Primaquine and Chloroquine has been found to be effective on chloroquine-resistant parasites.

It is believed that that the drug combination would work better as chloroquine would be prevented from leaking out by a parallel action of primaquine that acts to block the pores on the surface of the parasite's digestive system The finding promises hope and would be less expensive when compared to the existing treatment. This would also ensure that it is made available the poorest countries where need is greatest.

However, caution has to be taken because primaquine is not suitable for all patients, as it could trigger the break down of red blood cells in people with an enzyme deficiency. People would have to be tested for the same before the therapy can be instituted.

Page: 1

Related medicine news :

1. Abortion Pill approved by FDA
2. Another injectable contraceptive Pill approved by FDA
3. Levothyroxine Thyroid Hormone Replacement, Approved for Hypothyroidism
4. New FDA Approved Drug To Treat Migraine
5. Lose Weight With New Wonder Slimming FDA approved Prescription Drug
6. New FDA Approved Drug NATRECOR For Heart Failure Patients
7. Voice may be improved by surgery
8. New oral antiviral treatment of cold sores approved
9. Survival rates in breast cancer patients improved with "Dose Dense Chemotherapy"
10. ICU Survival can be improved by Antibiotic use
11. Survival rate not improved by invasive procedures
Post Your Comments:

(Date:11/26/2015)... TX (PRWEB) , ... November 26, 2015 , ... PRMA ... On November 19, 2015, our surgeons performed their 6,000th free flap breast reconstruction surgery! ... “We wake up every day excited to rebuild lives and it’s an honor to ...
(Date:11/26/2015)... ... November 26, 2015 , ... Pixel Film ... trailer titles with ProTrailer: Vintage. This newly styled ProTrailer pack comes with 30 ... with any font, giving users limitless opportunities to stylize and create designs quickly ...
(Date:11/26/2015)... ... ... Indosoft Inc., developer and distributor of the world-class Asterisk based contact center software Q-Suite, ... The new Q-Suite 6 platform is based on the latest Java Enterprise standards. By ... piece of software for many key components of the suite. Much of the suite ...
(Date:11/25/2015)... ... November 25, 2015 , ... ... Water For Empowerment ™ attracts volunteers together who want to combine talents ... women as key stakeholders in the process. The non-profit launched its first major ...
(Date:11/25/2015)... ... 2015 , ... Finnleo, a leader in the traditional and far-infrared sauna industry, ... far-infrared saunas. , For traditional saunas, Finnleo is offering 20% off ... and Finnleo uses only European Grade A Nordic White Spruce from sustainably grown trees. ...
Breaking Medicine News(10 mins):
(Date:11/26/2015)... , November 26, 2015 ... the "Self Administration of High Viscosity Drugs" ... ) has announced the addition of the ... report to their offering. --> Research ... addition of the "Self Administration of High ...
(Date:11/26/2015)... DUBLIN , November 26, 2015 ... has announced the addition of the  ... in the European Cell Surface Marker ... Emerging Opportunities"  report to their offering.  ... announced the addition of the  "2016 ...
(Date:11/25/2015)... Nov. 25, 2015  Amgen (NASDAQ: AMGN ) ... (BLA) with the United States ... a biosimilar candidate to Humira ® (adalimumab). Amgen ... submitted to the FDA and represents Amgen,s first BLA ... E. Harper , M.D., executive vice president of Research ...
Breaking Medicine Technology: